Standardized Fecal Microbiota Transplantation for Crohn&Apos;s Diseases
Status:
Unknown status
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
The gut microbiota is considered to constitute a "microbial organ" which has pivotal roles
in the intestinal diseases and body's metabolism. Evidence from animal and human studies
strongly supports the link between intestinal bacteria and inflammatory bowel diseases
(IBD). Dozens of studies reported its efficacy in treatment of severe Clostridium difficile
colitis. Preliminary studies using FMT for Ulcerative Colitis (UC), Crohn's diseases (CD),
irritable bowel syndrome (IBS) and constipation have also met with some success. However,
the results on CD is very limited. This is an initial step into investigating the potential
efficacy of fecal bacteriotherapy for CD, the investigators propose to determine the
efficiency, durability and safety of FMT in a series of 30 patients with CD (included cased
according Montreal classification: Age > 14 years old, Location L1-3, Behavior B1-3 but
without perianal diseases).